308P - The effectiveness of neoadjuvant chemotherapy with recombinant tumor necrosis factor-thymosin-α1in locally advanced breast cancer and effect on tum...

Date 10 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Breast Cancer
Presenter Liubov Vladimirova
Citation Annals of Oncology (2016) 27 (6): 68-99. 10.1093/annonc/mdw365
Authors L. Vladimirova1, N. Podzorova1, E. Nepomnyaschaya2, I. Novikova3, E. Ulyanova3, G. Zakora3, E. Bondarenko4
  • 1Department Of Antitumor Drug Therapy, Rostov Research Oncology Institute, 344037 - Rostov-on-Don/RU
  • 2Department Of Patology, Rostov Research Oncology Institute, 344037 - Rostov-on-Don/RU
  • 3Laboratory Of Immunophenotyping Of Tumors, Rostov Research Institute of Oncology, Rostov on Don/RU
  • 4Laboratory Of Immunophenotyping Of Tumors, Rostov Research Institute of Oncology, 344037 - Rostov on Don/RU



The little is known about the influence of recombinant hybrid protein of tumor necrosis factor-alpha-thymosin-alpha1 (TNF-T) on angiogenesis in breast cancer (ВС). The aim of the study was to investigate markers of angiogenesis and vascular proliferation in the tumor and to evaluate the efficacy of TNF-T in the neoadjuvant treatment of locally advanced breast cancer (LABC).


Eligibility criteria included LABC of IIB-IIIB stages, ECOG ≤ 1, adequate kidney, liver and bone marrow function, no brain metastases. TNF-T 200000 IU was used peritumorally (injected around the tumor) on D1-5 (30 min before cytostatics injection), combined with standard FAC or PA regimens. The factors of angiogenesis CD31 and CD34 were studied in trephine-biopsy specimens before treatment and in postsurgical biopsies of the tumor after TNF-T courses.


82 women were recruited between April 2012 – October 2013 (mean age 53.3 ± 1.1 years). Group A (30 pts) received TNF-T combined to PA (17) and FAC (13) up to 6 courses. Group B (52pts) received standard PA (31) and FAC (21). Tumor response (TR) in Group A was 80% and in Group B 71.9% (p 


TNF-T injected peritumorally allows to increase the antitumor activity of cytostatics (CR) which is of great importance for survival in LABC. The data acquired in the biopsies show that the recombinant protein of TNF-T has the suppressive effect on angiogenesis.

Clinical trial identification

Legal entity responsible for the study

Rostov Institute of Oncology


Rostov Institute of Oncology


All authors have declared no conflicts of interest.